In the just-released Fortune 500 List 2014, CR was ranked 143rd with a turnover of US$ 66 billion, 44 placed advanced compared with the list for 2013.

CR applied for inclusion in the list in 2010 and was ranked 395th. Since then, CR’s ranking in the list has been rising at a remarkable rate: 346th in 2011, 233rd in 2012, 187th in 2013 and 143rd in 2014, with its ranking rising 252 places in the five years. In 2013, CR realized a turnover of CNY 405.5 billion, a year-on-year increase of 23%, a total profit of CNY 36.3 billion, a year-on-year increase of 17%, and a total profit payable to shareholders of CNY 12.5 billion, a year-on-year increase of 4%. As of the end of 2013, the total asset of the Group reached CNY 848.9 billion with a year-o-year increase of 16%.

CR focused on trade before 2000. In 2001, CR formulated and began to implement its development strategy of “reaching to the mainland China from Hong Kong” and “centering on industrial development”. After over 10 years of unremitting efforts, CR has developed a dozen of leading enterprises with robust competency in many industries, with its overall competency rapidly enhanced and its leading status in many industries constantly consolidated and promoted. So far, CR has become a most competitive enterprise with diversified businesses in Mainland China and Hong Kong, with seven business sectors engaging in industries of fierce competition, of which CR Enterprise and CR Pharmaceutical have realized a turnover of HK$ 100 billion.

It is also reported that the number of enterprises based in China (including Hong Kong and Taiwan) listed in Fortune 500 sets another record, increasing from 95 in 2013 to 100. CR was ranked 24th among the Chinese enterprises listed, two placed higher than in 2013.